If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
349
results.
Updated on
14/09/2026 [08:02:00]
Results 225 to 250 of 349
Absstract of: CN122484254A
本发明涉及生物检测与体外诊断技术领域，尤其涉及一种基于MS2病毒样颗粒装载DNA的蛋白质检测方法、信号报告单元及试剂盒。方法通过将带有包装位点和检测标签序列的DNA包裹于MS2病毒样颗粒内部，并对颗粒表面进行功能化修饰，使其作为信号报告单元参与靶蛋白的夹心免疫识别；在完成特异结合后，经洗涤及核酸酶去背景处理，再对颗粒内部DNA进行扩增检测，从而实现对目标蛋白的定性和/或定量分析。本发明兼具免疫识别的高特异性、核酸扩增的高灵敏度以及MS2病毒样颗粒对内部核酸的保护作用，具有背景低、抗干扰能力强、检测灵敏度高和适于复杂生物样本检测等优点，适用于Aβ1‑42等低丰度蛋白标志物的检测。
Absstract of: CN122487652A
本发明涉及外周血血清中组织蛋白酶H在阿尔兹海默诊治中的用途，属于生物技术领域。本发明通过对CatH在AD相关样本中的表达/活性特征及其与疾病发生发展关系的研究与验证，确立血清中CatH作为AD新的诊疗靶点/生物标志物，并据此实现外周体液检测用于筛查、辅助诊断，同时为针对CatH 的抑制剂筛选与外周干预药物开发提供依据。
Absstract of: CN122484279A
0001 本发明适用于生物医学及分子诊断技术领域，提供了一种腺苷酸环化酶8作为阿尔茨海默症生物标志物的应用，本发明首次发现并证实，腺苷酸环化酶8在阿尔茨海默症患者及模型小鼠的海马组织中表达水平显著升高，且其在外周血液中的表达变化与海马组织呈现高度一致性。因此，通过检测受试者血液等离体样本中腺苷酸环化酶8的表达水平，即可反映海马组织的病理改变，用于阿尔茨海默症的辅助诊断、病情评估或风险筛查。本发明突破了无法活体获取海马组织进行检测的临床限制，提供了一种无创、简便、特异性强、灵敏度高的外周血生物标志物，适用于大规模人群筛查与长期病情监测，具有显著的临床实用价值和产业化前景。
Absstract of: CN122487677A
0001 本发明提供了一种PD‑MCI标志物及其筛选方法和应用，该PD‑MCI标志物为PLEKHH2、CA1和WDR1。在本发明中通过识别的"神经连接病"机制为治疗开发开辟了新途径，而药物重定位候选药物建立了临床前验证和临床试验的明确下一步。
Absstract of: FR3171721A1
L’invention concerne un dispositif permettant de mesurer le niveau d'une molécule cible telle qu'une protéine dans un échantillon de fluide d'un sujet, le dispositif comprenant un composant d'échantillonnage pour prélever le fluide du sujet ; un composant de quantification pour quantifier le niveau de la protéine cible dans l'échantillon de fluide ; et un composant de transport pour transporter le fluide du composant d'échantillonnage au composant de quantification. Figure de l’abrégé : Figure 1
Absstract of: CN122484126A
0001 本发明公开了一种pTau231适配体、pTau231探针、电化学生物传感器及构建方法，属于生物检测技术领域，所述电化学生物传感器以pTau231适配体、pTau231探针为核心生物识别元件，结合免疫磁珠富集模块、TDT酶促信号放大模块和靶标探针诱导ZIF‑8原位生长信号放大模块构建而成，用于超灵敏检测pTau231蛋白。该电化学生物传感器结合了免疫磁珠富集、TDT酶促信号放大和ZIF‑8原位生长信号放大三大模块，实现了多重信号放大与高效信号转换，将蛋白信号转为核酸信号，再转为可测量的强电化学信号，实现了低丰度pTau231的高灵敏检测，检测线性范围宽，可达
。
Absstract of: CN122487661A
0001 本申请涉及生物检测技术领域，具体公开了一种多重数字式蛋白检测方法。本申请利用微米级亲水修饰磁珠作为模板，通过使用涡旋振荡生成均一尺寸液滴；该检测方法不需要复杂的微流控系统、芯片或仪器产生均一的液滴，操作简单，对设备依赖程度低，可在几秒内完成反应试剂的快速分割，以磁珠为模板的液滴尺寸均一。本申请可以实现磁珠高利用率，基于振荡式的磁珠液滴生成技术避免了传统数字ELISA方法中装载方式限制导致磁珠利用率低的问题，提高检测灵敏度。本申请通过磁珠的大小、荧光、颜色、形貌进行组合编码，结合基于磁珠的涡旋液滴生成技术实现了多重数字式蛋白检测方法。
Absstract of: CN122484253A
0001 本发明公开了一种基于斑马鱼评价样品激活乙醛脱氢酶功效的方法。其首先构造斑马鱼评价模型，通过酒精暴露幼鱼后检测待乙醛脱氢酶活性，若样品实验组酶活性显著高于模型组，则判定待测样品具有激活功效。本发明能在活体水平上快速、直观地评价候选物质对乙醛脱氢酶（ALDH）的激活能力，从而筛选出能够有效加速乙醛清除、减轻乙醛毒性的活性成分。
Absstract of: WO2025024817A1
Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.
Absstract of: WO2024256685A1
The present invention relates to a modified secreted AY-WB protein 5 (SAP05) protein, and in particular the use of the modified SAP05 protein as part of a fusion compound for use in ubiquitin-independent protein degradation. The invention also relates to methods for the use of the fusion compound in targeted protein degradation, modulating physiological responses and therapy.
Absstract of: WO2025118073A1
The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
Absstract of: US20260217847A1
The present invention provides an anti-TfR1 single-domain antibody and a use thereof. The single-domain antibody includes a heavy chain variable region, wherein the heavy chain variable region includes a heavy chain CDR1 as shown in any one of SEQ ID NO: 53-SEQ ID NO: 60, a heavy chain CDR2 as shown in any one of SEQ ID NO: 61-SEQ ID NO: 72, and a heavy chain CDR3 as shown in any one of SEQ ID NO: 73-SEQ ID NO: 82.
Absstract of: US20260219284A1
Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of brain injuries, especially mild traumatic brain injury (mTBI) or concussion, are based upon detection of changes in levels of certain protein biomarkers in a subject undergoing testing, or upon detection of changes in levels of certain protein biomarkers in conjunction with neuroimaging analyses to detect changes in vascular or blood brain barrier (BBB) permeability in the brain, or to detect damage to fiber tracts in the brain, in which changes in biomarker levels correlate with detection of changes in BBB permeability or in brain fiber tract or white matter damage in a subject with brain injury such as mTBI or concussion.
Absstract of: WO2026159152A1
The present invention relates to a method for identifying test molecules capable of binding an oligomeric target protein and a RING-type E3 ligase in the presence of a fusion protein, and a cell expressing said fusion protein.
Absstract of: WO2026160244A1
A visualization agent for visualizing the aggregation state of a protein according to an embodiment contains a chemical probe molecule that binds to the protein in an aggregated state to form a complex. The chemical probe molecule is an aminocoumarin analog having a leaving group that leaves due to the formation of the complex. A method for visualizing the aggregation state of a protein according to an embodiment comprises: a contact step for bringing a visualization agent into contact with an aggregated protein; and a detection step for detecting the fluorescence of a complex of the aggregated protein and the visualization agent.
Absstract of: WO2026161305A2
Disclosed herein are conformationally stable variants of a single-chain circular permuted caspase, crystalline forms thereof, and methods of their preparation and use.
Absstract of: WO2026161463A1
Disclosed is a method of diagnosing a subject with ALS, the method including measuring the amount of OxPL on apolipoprotein E, E2, E3 and/or E4.
Absstract of: US20260216274A1
A method of treating a patient with moderate-to-severee traumatic brain injury (TBI) undergoing emergency craniotomy includes administering, in addition to orthodox therapy (OT), intravenous Xingnaojing (XNJ) for seven consecutive days in an intensive care setting, wherein acute postoperative neurological recovery is improved as measured by Glasgow Coma Scale (GCS) during postoperative Days 1, 3, 5, and 7, wherein long-term functional outcome is improved as measured by Glasgow Outcome Scale (GOS) and Karnofsky Performance Status (KPS) at 30 and 90 days, and wherein secondary-injury biomarkers are modulated by reducing serum S100B and preserving or restoring serum superoxide dismutase (SOD) activity relative to OT alone.
Absstract of: WO2026160417A1
The present invention addresses the problem of providing: a device, a method, and a program for easily, quickly, and accurately classifying and/or identifying a cell type of a living or fixed cell, particularly a cell of the nervous system, head, or the like; and a neural network training method for the device, the method, or the program. In the present invention, a neural network is trained by using two-dimensional and black-and-white training image data based on captured images of stained cell nuclei and training data including information related to cell types corresponding to the cells, thereby making it possible to inexpensively, quickly, and easily classify/identify a cell type with high accuracy on the basis of the image data of the stained cell nuclei for cells contained in a specimen such as cultured cells and tissue sections.
Absstract of: WO2026161273A1
Disclosed herein are antibodies, including anti-GPl antibodies that cross-react with more than one New World arenavirus and methods of using the anti-GPl antibodies.
Absstract of: WO2026160477A1
The present disclosure provides a novel technique for diagnosing STING-related diseases. Specifically, the present disclosure provides: a method comprising Step (A) for measuring a cyclic dinucleotide (CDN) present in a subject or obtaining information on the presence or level of the CDN, Step (B) for determining whether the CDN is derived from the subject and/or derived from a microorganism (parasite) expected to be contained in the subject, and Step (C) for diagnosing a STING-related disease or condition on the basis of the result of the determination; a therapeutic method related thereto; and the like.
Absstract of: WO2025024816A1
The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzode,gquinoline-10,11-diol for the treatment of diseases mediated by protein expressions and gene regulations, as well as the use of personalized medicine approach.
Absstract of: US20260219277A1
The present invention relates to a fluorescent compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof; and a composition for detecting gingipain, composition for diagnosing Porphyromonas gingivalis (P. gingivalis) infection or antibacterial composition against P. gingivalis using the same:
Absstract of: WO2026158729A2
Provided in the present application are a pathogenic factor of neurodegenerative diseases and the use thereof. The pathogenic factor of neurodegenerative diseases is a PSAP-GPR37-IL-6 signaling axis. The present application specifies for the first time the action mechanism of the PSAP-GPR37-IL-6 signaling axis as a pathogenic factor of neurodegenerative diseases (especially Parkinson's disease), and reveals that oligodendrocytes regulate the molecular pathway of neuroinflammation and neurodegenerative changes via the signaling axis, thus filling the research gap in the prior art regarding the participation of oligodendrocytes in the pathogenesis of PD.
Nº publicación: US20260215689A1 30/07/2026
Applicant:
OMNI MEDSCI INC [US]
Omni Medsci, Inc.
Absstract of: US20260215689A1
0000 Smart glasses have an outward side and an inward side facing a user. A light source is attached to the outward side emits a light beam. One or more cameras are attached to the outward side to capture images or videos. The smart glasses include a processor, speakers, and one or more microphones that receive voice control or interactions. The smart glasses are coupled to a non-transitory computer readable medium and a smart phone or a tablet. The smart glasses interact with a multi-modal generative artificial intelligence assistant including a transformer with self-attention and position encoding layers that performs computer vision and natural language processing. The glasses may also have displays, touch sensors, memory, machine learning and gesture analysis, and the ability to recognize an object. The glasses may also be coupled to a wearable device with contact-based sensors.
BOPI
Electronic site
